Hide metadata

dc.date.accessioned2020-08-17T18:41:54Z
dc.date.available2020-08-17T18:41:54Z
dc.date.created2020-07-30T13:11:29Z
dc.date.issued2020
dc.identifier.citationCheng, Socheat Gossop, Michael Kristoffersen, Espen Saxhaug Grambaite, Ramune Lundqvist, Anders Christofer . Association between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional study. BMJ Open. 2020
dc.identifier.urihttp://hdl.handle.net/10852/78444
dc.description.abstractObjectives Central nervous system depressants (CNSDs) such as opioids, benzodiazepine and Z-hypnotics are commonly used. However, CNSDs may influence cognitive function, especially in older hospitalised patients with comorbidities. The aim was to examine the association between CNSD use and cognitive function in older patients. We assessed global and domain specific cognitive function, among hospitalised older patients, including covariates for comorbidity, anxiety and depression. Design Cross-sectional hospital-based study. Settings Data was collected consecutively from inpatients at somatic wards of a general university hospital. Participants Older patients between 65 and 90 years with/without CNSD use for ≥4 weeks. Outcome measures The main outcome was cognitive function assessed by Cognistat. Secondary outcomes were routine clinical tests in the wards (mini-mental state examination (MMSE), trail making test (TMT) A and B, and clock drawing tests). Analyses were bivariate and multiple linear regression, adjusted for age, gender, and education. Covariates were comorbidity, depression and anxiety scores. Results The main result indicated that CNSD users (n=100) had (β=–3.4, 95% CI 6.27 to –0.58, p=0.017) lower Cognistat score than non-users (n=146), adjusted for age, gender, education, anxiety and depression, but not significant when including covariate for comorbidity (β= –2.50 - 5.45; –0.46, p=0.097). Comorbidity was associated with cognitive function (β=−0.77, 95% CI −1.22 to −0.14, p=0.014). Cognistat subdimensions associated with CNSD use were language (p=0.017) and calculation (p=0.003). In clock drawing test, users had lower scores than non-users (β=−0.80, 95% CI 1.24 to −0.36, p=0.004), but no significant difference was found with MMSE and TMT A or B. Z-hypnotics were associated with reduced cognitive function. Conclusion Among older hospitalised patients, global cognition and specific cognitive functions were associated with long-term use of CNSD medication as well as with somatic comorbidity.
dc.languageEN
dc.publisherBMJ Publishing Group
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleAssociation between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional study
dc.typeJournal article
dc.creator.authorCheng, Socheat
dc.creator.authorGossop, Michael
dc.creator.authorKristoffersen, Espen Saxhaug
dc.creator.authorGrambaite, Ramune
dc.creator.authorLundqvist, Anders Christofer
cristin.unitcode185,52,15,0
cristin.unitnameAvdeling for allmennmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1821056
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMJ Open&rft.volume=&rft.spage=&rft.date=2020
dc.identifier.jtitleBMJ Open
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2020-038432
dc.identifier.urnURN:NBN:no-81549
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2044-6055
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/78444/2/article2.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International